This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaseb, A. O. Articles by Reddy, G. P.-V. Search for Related Content PubMed PubMed Citation Articles by Kaseb, A. O. Articles by Reddy, G. P.-V.

Androgen Receptor– and E2F-1–Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer

¹ Department of Hematology/Oncology and ² Vattikuti Urology Institute, Henry Ford Hospital; ³ Barbara Ann Karmanos Cancer Institute; and ⁴ Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan

Requests for reprints: G. Prem-Veer Reddy, Vattikuti Urology Institute, Henry Ford Health System, One Ford Place, 2D, Detroit, MI 458202. Phone: 313-874-5991; E-mail: Preddy1{at}hfhs.org.

Relapse of prostate cancer after androgen ablation therapy is hormone-refractory, with continued tumor growth being dependent on the androgen receptor (AR). E2F-1, a regulator of cell proliferation and viability, reportedly plays a role in the development of hormone-refractory prostate cancer. Thymoquinone is a component of Nigella sativa, an herb used for thousands of years for culinary and medicinal purposes in Asian and Middle Eastern countries and has been reported to have an antineoplastic effect both in vitro and in vivo. We observed that thymoquinone inhibited DNA synthesis, proliferation, and viability of cancerous (LNCaP, C4-B, DU145, and PC-3) but not noncancerous (BPH-1) prostate epithelial cells by down-regulating AR and E2F-1. In LNCaP cells, this was associated with a dramatic increase in p21^Cip1, p27^Kip1, and Bax. Thymoquinone blunted progression of synchronized LNCaP cells from G₁ to S phase, with a concomitant decrease in AR and E2F-1 as well as the E2F-1-regulated proteins necessary for cell cycle progression. In a xenograft prostate tumor model, thymoquinone inhibited growth of C4-2B–derived tumors in nude mice. This in vivo suppression of tumor growth, as with C4-2B cell growth in culture, was associated with a dramatic decrease in AR, E2F-1, and cyclin A as determined by Western blot of tissue extracts. Tissue immunohistochemical staining confirmed a marked reduction in E2F-1 and showed induction of apoptosis on terminal deoxyribonucleotidyl transferase–mediated dUTP nick end labeling assay. These findings show that thymoquinone suppresses the expression of AR and E2F-1 necessary for proliferation and viability of androgen-sensitive as well as androgen-independent prostate cancer cells both in vitro and in vivo and, moreover, produced no noticeable side effects in mice. We conclude that thymoquinone, a naturally occurring herbal product, may prove to be effective in treating hormone-sensitive as well as hormone-refractory prostate cancer. Furthermore, because of its selective effect on cancer cells, we believe that thymoquinone can also be used safely to help prevent the development of prostate cancer. [Cancer Res 2007;67(16):7782–8]

This article has been cited by other articles:

				S. Banerjee, A. O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, F. H. Sarkar, and R. M. Mohammad Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer Cancer Res., July 1, 2009; 69(13): 5575 - 5583. [Abstract] [Full Text] [PDF]

				T. Yi, S.-G. Cho, Z. Yi, X. Pang, M. Rodriguez, Y. Wang, G. Sethi, B. B. Aggarwal, and M. Liu Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways Mol. Cancer Ther., July 1, 2008; 7(7): 1789 - 1796. [Abstract] [Full Text] [PDF]

				T. Yi, Z. Yi, S.-G. Cho, J. Luo, M. K. Pandey, B. B. Aggarwal, and M. Liu Gambogic Acid Inhibits Angiogenesis and Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2 Signaling Cancer Res., March 15, 2008; 68(6): 1843 - 1850. [Abstract] [Full Text] [PDF]